News and Media

Press Releases

2018

May 30, 2018
Casebia Therapeutics Appoints Amy Jennings to Head its Regulatory Affairs

2017

November 13, 2017
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

September 27, 2017
Casebia Therapeutics Announces License and Collaboration Agreements with Seattle Children’s Research Institute

September 8, 2017
Casebia Therapeutics Strengthens Leadership Team with Two Key Appointments

June 28, 2017
Casebia Therapeutics names Robin A. Walker as Vice President, Head of Legal

May 11, 2017
Casebia Therapeutics Expands Leadership Team

March 14, 2017
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with MaxCyte

2016

November 1, 2016
Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer

In the News

2018

May 3, 2018
Evolving Industry Partnerships and Investments in Cell and Gene Therapies

2017

September 15, 2017
Boston Business Journal: Casebia Head of Legal Robin Walker named one of the 50 Most Influential People of Color in Healthcare & Life Sciences

Social Media

At #CasebiaTx, we work with #CRISPR/Cas9 gene editing technology to improve outcomes for patients like Ryanne #raredisease #hemophiliaA
https://t.co/IlO6r1uGUJ

Joint Statement from @CRISPRTX on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to #CRISPR/Cas9 Genome Editing Technology https://t.co/uH0s83ZCxM

See us on Twitter